alpha-1 antitrypsin


Also found in: Wikipedia.

alpha-1 antitrypsin

A 54-kD glycoprotein that inhibits proteolytic enzymes (proteases), trypsin, chymotrypsin, elastases in lysosomes, plasmin, thrombin, collagenase and others; serum A1AT is a so-called acute-phase reactant.

Increased A1AT
Inflammation, liver injury, increased oestrogen, pregnancy, malignancy, corticosteroid therapy.
 
Decreased A1AT
Heterozygous A1AT deficiency, emphysema, prematurity, protein-losing disorders; by immunohistochemistry, A1AT stains atypical fibroxanthoma, granular cell tumour and papillary carcinoma of the thyroid.
 
Ref range
2–4 g/L
References in periodicals archive ?
NASDAQ: ARWR) has dosed the first subjects in a Phase 1 clinical study of ARO-AAT, which is being developed as treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency, the company said.
Adverum Biotechnologies announced the completion of dosing and evaluation of patients in the first cohort of the ADVANCE Phase 1/2 clinical trial for alpha-1 antitrypsin deficiency.
Under the exclusive license the company plans to conduct a Phase II study for the treatment of alpha-1 antitrypsin deficiency, a congenital orphan condition.
Technavio has released a new market research report on the global alpha-1 antitrypsin drugs market, which is projected to reach almost $6 billion in market value by 2020.
April 2, 2015--Using patient-derived stem cells known as induced pluripotent stem cells (iPSC) to study the genetic lung/liver disease called alpha-1 antitrypsin (AAT) deficiency, researchers have for the first time created a disease signature that may help explain how abnormal protein leads to liver disease.
American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.
After washing step, membrane was reacted with 1000-fold diluted goat anti-human alpha-1 antitrypsin polyclonal antibody, conjugated with HRP (Abcam) for 3 hr.
Recommendations for expensive treatments made for a genetic disorder called alpha-1 antitrypsin deficiency should be withdrawn because the drugs have no benefit, scientists said.
AAT is a replacement therapy in individuals who lack the Alpha-1 Antitrypsin protein.
Washington, Dec 22 (ANI): People with single-gene mutations that cause them to have abnormally low levels of the protein alpha-1 antitrypsin are highly susceptible to emphysema-a progressive lung disease that causes severe shortness of breath.
5) With patients in their 30s or 40s exhibiting signs and symptoms suggestive of COPD, consider a work-up for alpha-1 antitrypsin deficiency.

Full browser ?